Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11254252 | 0.79 | GRIA1 (0.53) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL17278321 | 0.79 | LMNA (0.50) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL6571664 | 0.77 | GRIA1 (0.48) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL19711624 | 0.76 | GRIA1 (0.54) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL425895 | 0.75 | KMT2A (0.49) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL9891079 | 0.72 | GRIA1 (0.47) | GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL6570527 | 0.70 | GRIA1 (0.48) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL2353226 | 0.70 | GRIA1 (0.48) | GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL4379053 | 0.69 | DAO (0.43) | GRIA1GRIA2GRIA4GRIK5HPGD | |
| SCHEMBL6719212 | 0.68 | GRIA1 (0.43) | GRIA1GRIA2GRIA4GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-6294535-B1 | TREATING CANCER, WHICH COMPRISES ADMINISTERING TO A PATIENT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF A URACIL DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |